Transient Ischemic Attack (TIA)

A transient ischemic attack, TIA or mini-stroke, occurs when blood supply to part of the brain is briefly interrupted. The only difference between a TIA and a stroke is that with TIA the blockage is transient or temporary.

Transient Ischemic Attack (TIA)

Most TIAs last for a few minutes and are caused by an embolus dislodged from a carotid artery atherosclerotic plaque. Presence of infarction, or tissue death, is the main distinction between a TIA and a stroke.

Symptoms vary widely from person to person, depending on the area of the brain involved with most frequent symptoms being temporary loss of vision, difficulty speaking, weakness or  numbness on one side of the body.

An estimated 350,000 TIAs occur annually in the United States, 500,000 in Europe and 130,000 in Japan. Ten percent of patients who suffer a TIA may present with a stroke within 3 months, with half of those strokes occurring within 48 hours from TIA event.

Read more...

Transient Ischemic Attack (TIA)

A transient ischemic attack, TIA or mini-stroke, occurs when blood supply to part of the brain is briefly interrupted. The only difference between a TIA and a stroke is that with TIA the blockage is transient or temporary.

Transient Ischemic Attack (TIA)

Most TIAs last for a few minutes and are caused by an embolus dislodged from a carotid artery atherosclerotic plaque. Presence of infarction, or tissue death, is the main distinction between a TIA and a stroke.

Symptoms vary widely from person to person, depending on the area of the brain involved with most frequent symptoms being temporary loss of vision, difficulty speaking, weakness or  numbness on one side of the body.

An estimated 350,000 TIAs occur annually in the United States, 500,000 in Europe and 130,000 in Japan. Ten percent of patients who suffer a TIA may present with a stroke within 3 months, with half of those strokes occurring within 48 hours from TIA event.

Read more...

Abbott ACT I Carotid Stent Clinical Trial

Abbott Vascular ACT I is a prospective, randomized, multi-center trial that is enrolling a maximum of 1,658  patients, at up to 50 sites in North America.

ACT I is designed to demonstrate the non-inferiority of CAS when compared to carotid endarterectomy (CEA) for the treatment of asymptomatic carotid artery disease (CAD) in people at normal risk for surgery.

ACT I is using Abbott Vascular Emboshield BareWire Rapid Exchange Embolic Protection System with the Xact Rapid Exchange Carotid Stent System.

Read more...

Abbott ACT I Carotid Stent Clinical Trial

Abbott Vascular ACT I is a prospective, randomized, multi-center trial that is enrolling a maximum of 1,658  patients, at up to 50 sites in North America.

ACT I is designed to demonstrate the non-inferiority of CAS when compared to carotid endarterectomy (CEA) for the treatment of asymptomatic carotid artery disease (CAD) in people at normal risk for surgery.

ACT I is using Abbott Vascular Emboshield BareWire Rapid Exchange Embolic Protection System with the Xact Rapid Exchange Carotid Stent System.

Read more...

Richard Emmitt Sells 600,000 ev3 Shares

Richard Emmitt, a general partner at The Vertical Group and member of ev3 board of directors, sold $8.8 million worth of ev3 stock. The transaction was filed with SEC on Tuesday January 19th 2010, same day that J.P. Morgan upgraded the stock from Neutral to Overweight with a price target increase from $15 to $19.

Read more...

Richard Emmitt Sells 600,000 ev3 Shares

Richard Emmitt, a general partner at The Vertical Group and member of ev3 board of directors, sold $8.8 million worth of ev3 stock. The transaction was filed with SEC on Tuesday January 19th 2010, same day that J.P. Morgan upgraded the stock from Neutral to Overweight with a price target increase from $15 to $19.

Read more...

Stifel Raises Micrus Endovascular Target to $19

Following a meeting with Micrus management where they came away positive on the prospects of Micrus managing to achieve its stated revenue guidance of $84-87 million for fiscal 2010, Stifel Analysts raised their target to $19 from $15. They also indicated that Micrus will be able to drive significant operating margin improvement throughout the remainder of year.

Read more...